Head and Neck Cancer: New Treatment Combinations

We are comparing a new drug combination with a single drug for patients with locally advanced head and neck cancer. The aim is to see which treatment works better before starting chemoradiotherapy.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Brentuximab Vedotin
Brentuximab vedotin is a substance used to treat certain types of lymphoma by targeting cancer cells with the CD30 protein.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

MrG003
Hx008
Pucotenlimab

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Institut De Cancerologie De L Ouest
Oncology
Angers, France
Institut De Cancerologie De L Ouest
Medical oncology
Avignon, France
Institut Sainte Catherine
Oncology-Radiotherapy
Avignon, France

Sponsor: Groupe Oncologie Radiotherapie Tete Cou
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.